Grossman, H Barton <br/><br/>
Can Biomarkers Guide the Use of Neoadjuvant Chemotherapy in T2 Bladder Cancer?  [electronic resource] 

 -  European urology oncology  09 2019 
 - 597-602 p.  digital 
<br/><br/> Publication Type: Case Reports; Journal Article 
<br/><br/><label>ISSN: </label>2588-9311 
<br/><br/><label>Standard No.: </label>10.1016/j.euo.2019.06.002  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Combined Chemotherapy Protocols--economics<br/>Biomarkers, Tumor--analysis<br/>Clinical Decision-Making--methods<br/>Cystectomy<br/>DNA Damage<br/>DNA Repair<br/>Decision Support Techniques<br/>Guideline Adherence--standards<br/>Humans<br/>Male<br/>Middle Aged<br/>Neoadjuvant Therapy--economics<br/>Neoplasm Invasiveness--pathology<br/>Neoplasm Staging<br/>Patient Selection<br/>Practice Guidelines as Topic<br/>Predictive Value of Tests<br/>Prognosis<br/>Treatment Outcome<br/>Urinary Bladder--pathology<br/>Urinary Bladder Neoplasms--genetics